Clinical Trial Update: Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pactimibe (CS-505), an ACAT inhibitor, for slowing the progression of coronary heart disease; results address efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• Pactimibe (CS-505) (Pactimibe)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Coronary Heart Disease | Phase 2 | Status: COMPLETED